ACCESS Newswire

The Klein Law Firm

20.7.2021 16:37:02 CEST | ACCESS Newswire | Press release

Share
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of HMPT, LOTZ and RCAR

NEW YORK, NY / ACCESSWIRE / July 20, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

Home Point Capital Inc. (NASDAQ:HMPT)
This lawsuit is on behalf of all persons and entities other than Defendants that purchased or otherwise acquired Home Point common stock pursuant and/or traceable to the Company's January 29, 2021 initial public offering.

Lead Plaintiff Deadline: August 20, 2021

During the class period, Home Point Capital Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (i) Home Point's aggressive expansion of its broker partners would dramatically increase the Company's expenses; (ii) the mortgage industry was anticipating industry-wide decreased gain-on-sale margins as a result of rising interest rates in 2021 and Home Point would be subject to the same competitive pressures; (iii) accordingly, the Company had overstated its business and financial prospects; and (iv) as a result, the Offering Documents were materially false and/or misleading and failed to state information required to be stated therein.

Learn about your recoverable losses in HMPT: https://www.kleinstocklaw.com/pslra-1/home-point-capital-inc-loss-submission-form?id=17806&from=1

CarLotz, Inc. (NASDAQ:LOTZ)
Class Period: December 30, 2020 - May 25, 2021
Lead Plaintiff Deadline: September 7, 2021

The LOTZ lawsuit alleges CarLotz, Inc. made materially false and/or misleading statements and/or failed to disclose during the class period that: (1) due to a surge in inventory during the second half of fiscal 2020, CarLotz was experiencing a "logjam" resulting in slower processing and higher days to sell; (2) as a result, the Company's gross profit per unit would be negatively impacted; (3) to minimize returns to the corporate vehicle sourcing partner responsible for more than 60% of CarLotz's inventory, the Company was offering aggressive pricing; (4) as a result, CarLotz's gross profit per unit forecast was likely inflated; (5) this Company's corporate vehicle sourcing partner would likely pause consignments to the Company due to market conditions, including increasing wholesale prices; and (6) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Learn about your recoverable losses in LOTZ: https://www.kleinstocklaw.com/pslra-1/carlotz-inc-loss-submission-form?id=17806&from=1

Renovacare, Inc. (OTC PINK:RCAR)
Class Period: August 14, 2017 - May 28, 2021
Lead Plaintiff Deadline: September 14, 2021

The RCAR lawsuit alleges that throughout the class period, Renovacare, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) at the direction of Harmel Rayat, RenovaCare engaged in a promotional campaign to issue misleading statements to artificially inflate the Company's stock price; (2) when the OTC Markets inquired, RenovaCare and Mr. Rayat issued a materially false and misleading press release claiming that no director, officer, or controlling shareholder had any involvement in the purported third party's promotional materials; (3) as a result of the foregoing, the Company's disclosure controls and procedures were defective; and (4) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Learn about your recoverable losses in RCAR: https://www.kleinstocklaw.com/pslra-1/renovacare-inc-loss-submission-form?id=17806&from=1

To view this piece of content from www.accesswire.com, please give your consent at the top of this page.

Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

SOURCE: The Klein Law Firm



View source version on accesswire.com:
https://www.accesswire.com/656281/The-Klein-Law-Firm-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders-of-HMPT-LOTZ-and-RCAR

To view this piece of content from www.accesswire.com, please give your consent at the top of this page.

About ACCESS Newswire

DK

Subscribe to releases from ACCESS Newswire

Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from ACCESS Newswire

GoodData Kicks Off 2026 with MCP Server Launch and Major Enterprise Wins15.4.2026 12:00:00 CEST | Press release

Financial services wins and three platform launches signal accelerating enterprise demand for agentic analytics. SAN FRANCISCO, CA / ACCESS Newswire / April 15, 2026 / GoodData, a leading AI-native decision intelligence platform, today announced strong Q1 2026 results driven by the launch of its MCP Server for agentic analytics, significant new contracts in global financial services, and continued expansion into new markets. The quarter built on a record-breaking 2025, reinforcing GoodData's position as the platform enterprises trust to move AI from pilot to production. Continued growth across enterprise and financial services GoodData's commercial momentum remained strong throughout Q1, with notable wins across the enterprise and financial sectors. The company secured a new three-year contract with one of the world's largest asset managers, and a key long-term customer in global payments renewed for three years while expanding its enterprise license. "Our Q1 results demonstrate that t

GoodData Kicks Off 2026 with MCP Server Launch and Major Enterprise Wins15.4.2026 12:00:00 CEST | Press release

Financial services wins and three platform launches signal accelerating enterprise demand for agentic analytics. SAN FRANCISCO, CA / ACCESS Newswire / April 15, 2026 / GoodData, a leading AI-native decision intelligence platform, today announced strong Q1 2026 results driven by the launch of its MCP Server for agentic analytics, significant new contracts in global financial services, and continued expansion into new markets. The quarter built on a record-breaking 2025, reinforcing GoodData's position as the platform enterprises trust to move AI from pilot to production. Continued growth across enterprise and financial services GoodData's commercial momentum remained strong throughout Q1, with notable wins across the enterprise and financial sectors. The company secured a new three-year contract with one of the world's largest asset managers, and a key long-term customer in global payments renewed for three years while expanding its enterprise license. "Our Q1 results demonstrate that t

OBI Pharma Announces Ten Poster Presentations at the AACR 2026 Annual Meeting for GlycOBI(R) Glycan-based Site-Specific Antibody-Drug Conjugates (ADCs): Mono and Bi-Specific (inc. Dual payload) and Obrion(TM) ADC enabling technologies15.4.2026 10:40:00 CEST | Press release

Poster Presentations featuring the latest advancements on anti-TROP2 (OBI 902) and Nectin-4 (OBI 904) ADCs, anti-TROP2/HER2 BsADC (OBI 201), anti-cMET/HER3Bs-Dual Payload ADC (OBI 221),and OBI's novel Obrion ™ ADC enabling technologies(GlycOBI ® and GlycOBI DUO ®). TAIPEI, TW / ACCESS Newswire / April 15, 2026 / OBI Pharma, Inc. (TPEx:4174.TWO) today announced its presence at AACR 2026, highlighted by ten poster presentations, showcasing the transformative potential of the GlycOBI® platform. Conventional ADCs often face limitations due to random conjugation, resulting in heterogeneous Drug-to-Antibody Ratios (DAR), suboptimal stability, and narrow therapeutic windows. In contrast, the OBI site-specific glycan-based technology enables a highly homogeneous DAR, translating into improved PK/PD profiles, and reduced off-target toxicity, as demonstrated by OBI's lead programs, OBI-902 and OBI-904. We are further advancing precision oncology through our next-generation bispecific (OBI-201) a

OBI Pharma Announces Ten Poster Presentations at the AACR 2026 Annual Meeting for GlycOBI(R) Glycan-based Site-Specific Antibody-Drug Conjugates (ADCs): Mono and Bi-Specific (inc. Dual payload) and Obrion(TM) ADC enabling technologies15.4.2026 10:40:00 CEST | Press release

Poster Presentations featuring the latest advancements on anti-TROP2 (OBI 902) and Nectin-4 (OBI 904) ADCs, anti-TROP2/HER2 BsADC (OBI 201), anti-cMET/HER3Bs-Dual Payload ADC (OBI 221),and OBI's novel Obrion ™ ADC enabling technologies(GlycOBI ® and GlycOBI DUO ®). TAIPEI, TW / ACCESS Newswire / April 15, 2026 / OBI Pharma, Inc. (TPEx:4174.TWO) today announced its presence at AACR 2026, highlighted by ten poster presentations, showcasing the transformative potential of the GlycOBI® platform. Conventional ADCs often face limitations due to random conjugation, resulting in heterogeneous Drug-to-Antibody Ratios (DAR), suboptimal stability, and narrow therapeutic windows. In contrast, the OBI site-specific glycan-based technology enables a highly homogeneous DAR, translating into improved PK/PD profiles, and reduced off-target toxicity, as demonstrated by OBI's lead programs, OBI-902 and OBI-904. We are further advancing precision oncology through our next-generation bispecific (OBI-201) a

IDC Defines the Next Era of Technology Intelligence with the Introduction of IDC Quanta(TM) at Directions 20268.4.2026 17:15:00 CEST | Press release

New AI-powered platform establishes an embedded intelligence layer for the AI economy, delivering decision-grade insight BOSTON, MA / ACCESS Newswire / April 8, 2026 / IDC today opened IDC Directions 2026, its flagship client event, bringing together technology leaders, analysts, and industry experts to examine the forces reshaping the global technology market and to introduce a major evolution in how technology intelligence is delivered. At the center of this year's event is IDC Quanta™, a new AI-powered platform that establishes what IDC defines as the technology intelligence layer for the AI economy. As artificial intelligence accelerates the pace of business and compresses decision cycles, IDC is redefining its role from a destination for research and data to an embedded intelligence capability that delivers trusted insight directly into the workflows where decisions are made. "AI is compressing time across the entire technology market, and that breaks the traditional research mode

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye